NeuroSense Completes Dosing of Last Patient in ALS Trial
NeuroSense Therapeutics (Nasdaq: NRSN) has dosed the last patient in the double-blind segment of its Phase 2b amyotrophic lateral sclerosis (ALS) trial of PrimeC (PARADIGM). Clinical efficacy results, including safety, tolerability, quality of life and overall survival, are expected in December 2023.
Alon Ben Noon, CEO of NeuroSense, said, “We are excited to soon begin sharing the results of the double-blind segment of our Phase 2b trial. We would like to thank the trial participants, their caregivers and families, as well as the sites’ Principal Investigators and study coordinators for their tremendous contribution to PARADIGM.”
Highlights
Sixty-nine people living with ALS in Canada, Italy, and Israel were enrolled in the multinational, randomized, double-blind, placebo-controlled Phase 2b clinical trial of PrimeC in ALS.
PrimeC is designed to synergistically target several key ALS mechanisms that contribute to motor neuron degeneration to inhibit the progression of ALS.
PrimeC has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
ALS is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis.
About NeuroSense Therapeutics
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
